IBDEI1HS ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23866,1,2,0)
 ;;=2^90653
 ;;^UTILITY(U,$J,358.3,23866,1,3,0)
 ;;=3^Flu Vaccine (Fluad TIV PFS)
 ;;^UTILITY(U,$J,358.3,23867,0)
 ;;=B18.2^^107^1196^38
 ;;^UTILITY(U,$J,358.3,23867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23867,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,23867,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,23867,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,23868,0)
 ;;=E11.9^^107^1196^23
 ;;^UTILITY(U,$J,358.3,23868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23868,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,23868,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,23868,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,23869,0)
 ;;=E11.40^^107^1196^21
 ;;^UTILITY(U,$J,358.3,23869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23869,1,3,0)
 ;;=3^DM Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,23869,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,23869,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,23870,0)
 ;;=E78.2^^107^1196^39
 ;;^UTILITY(U,$J,358.3,23870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23870,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,23870,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,23870,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,23871,0)
 ;;=E78.5^^107^1196^40
 ;;^UTILITY(U,$J,358.3,23871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23871,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,23871,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,23871,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,23872,0)
 ;;=E66.3^^107^1196^57
 ;;^UTILITY(U,$J,358.3,23872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23872,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,23872,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,23872,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,23873,0)
 ;;=F17.200^^107^1196^50
 ;;^UTILITY(U,$J,358.3,23873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23873,1,3,0)
 ;;=3^Nicotine Dependence,Unspec
 ;;^UTILITY(U,$J,358.3,23873,1,4,0)
 ;;=4^F17.200
 ;;^UTILITY(U,$J,358.3,23873,2)
 ;;=^5003360
 ;;^UTILITY(U,$J,358.3,23874,0)
 ;;=G43.909^^107^1196^48
 ;;^UTILITY(U,$J,358.3,23874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23874,1,3,0)
 ;;=3^Migraine,Unspec
 ;;^UTILITY(U,$J,358.3,23874,1,4,0)
 ;;=4^G43.909
 ;;^UTILITY(U,$J,358.3,23874,2)
 ;;=^5003909
 ;;^UTILITY(U,$J,358.3,23875,0)
 ;;=H91.93^^107^1196^34
 ;;^UTILITY(U,$J,358.3,23875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23875,1,3,0)
 ;;=3^Hearing Loss,Bilateral
 ;;^UTILITY(U,$J,358.3,23875,1,4,0)
 ;;=4^H91.93
 ;;^UTILITY(U,$J,358.3,23875,2)
 ;;=^5006944
 ;;^UTILITY(U,$J,358.3,23876,0)
 ;;=I10.^^107^1196^41
 ;;^UTILITY(U,$J,358.3,23876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23876,1,3,0)
 ;;=3^Hypertension
 ;;^UTILITY(U,$J,358.3,23876,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,23876,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,23877,0)
 ;;=I50.9^^107^1196^17
 ;;^UTILITY(U,$J,358.3,23877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23877,1,3,0)
 ;;=3^Congestive Heart Failure,Unspec
 ;;^UTILITY(U,$J,358.3,23877,1,4,0)
 ;;=4^I50.9
 ;;^UTILITY(U,$J,358.3,23877,2)
 ;;=^5007251
 ;;^UTILITY(U,$J,358.3,23878,0)
 ;;=I67.89^^107^1196^16
 ;;^UTILITY(U,$J,358.3,23878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23878,1,3,0)
 ;;=3^Cerebrovascular Disease,Oth
 ;;^UTILITY(U,$J,358.3,23878,1,4,0)
 ;;=4^I67.89
 ;;^UTILITY(U,$J,358.3,23878,2)
 ;;=^5007388
 ;;^UTILITY(U,$J,358.3,23879,0)
 ;;=J45.909^^107^1196^4
 ;;^UTILITY(U,$J,358.3,23879,1,0)
 ;;=^358.31IA^4^2
